HCPCS Code M0232

Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, second dose
Code effective Jul 01, 2026

HCPCS Section
Medical services

M0232 is a valid 2026 HCPCS code meaning Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, second dose or (Inf tocilizumab-bavi 2nd dos) for short. HCPCS M0232 has been effective since 07/01/2026 and applies to Pneumococcal/flu vaccine.

HCPCS Code Details - M0232

HCPCS Level II Code
Section M - Medical services
HCPCS Code M0232
Description

Long description:
Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, second dose

Short description:
Inf tocilizumab-bavi 2nd dos

HCPCS Pricing indicator 54 - Vaccinations
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Coverage code C - Carrier judgment
BETOS2 code O1G - Immunizations/Vaccinations
HCPCS Action code A - Add procedure or modifier code
Type of service V - Pneumococcal/flu vaccine
Effective date Effective Jul 01, 2026
Date added Added Jul 01, 2026

See also

  • HCPCS M0231 · Intravenous infusion, tocilizumabbavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, includes infusion and post administration monitoring, first dose

  • HCPCS M0233 · Intravenous infusion, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose

1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 7/13/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.